Lighthouse Pharmaceuticals’ plan to become a beacon of hope for Alzheimer’s disease patients has received almost $50 million ...

The Cleveland Clinic's Nathan Pennell, M.D., Ph.D., is switching to the Big Pharma realm to head up hematology and oncology ...

The Supreme Court is allowing the Trump administration to axe $783 million in federal research funding, reversing a lower ...

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered ...

Thermo Fisher Scientific cut the ribbon to open a highly automated manufacturing plant in North Carolina—featuring a ...

Arena BioWorks has laid off 30% of its workers 19 months after launching with $500 million and visions of bringing the Bell ...

More than two years after the Food and Drug Administration held a public workshop on measuring overall survival (OS) in ...

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine ...

Gilead Sciences has become the latest pharma to strengthen its in vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics.

Partnering with VantAI could give Halda a source of target-effector pairs for its next wave of prospects. The deal could be ...

In an update to their guidelines for treating high blood pressure, a group of cardiovascular medical societies has included a ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. | ...